AXA CEO Thomas Buberl says we are at the beginning of a revolution in obesity treatment. He shares details on how drugs like Ozempic will positively impact health insurers. He speaks on 'The David Rubenstein Show: Peer-to-Peer Conversations." This interview was recorded January 30 in New York.